Signal transduction networks in rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 62, Issue SUPPL. 2, 2003, Pages 86-89

  Hammaker, D ^a   Sweeney, S ^a   Firestein, G S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; I KAPPA B; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE; TRANSCRIPTION FACTOR AP 1;

APOPTOSIS; CELL PROLIFERATION; CELL STIMULATION; CONFERENCE PAPER; DISEASE COURSE; DRUG MECHANISM; ENZYME ANALYSIS; ENZYME SYNTHESIS; HUMAN; IMMUNOHISTOCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN TARGETING; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYNOVIOCYTE; SYNOVIUM;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; MAP KINASE SIGNALING SYSTEM; NF-KAPPA B; SIGNAL TRANSDUCTION;

EID: 0142156224     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.62.1.86     Document Type: Conference Paper

References (36)

1. Shouda T, Yoshida T, Hanada T, Wakioka T, Oishi M, Miyoshi K, et al. Induction of the cytokine signal regulator SOCS3/CIS3 as a therapeutic strategy for treating inflammatory arthritis. J Clin Invest 2001;108:1781-8.
2. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature 2001;410:37-40.
3. Tak PP, Firestein GS. NF-κB: a key player in inflammatory diseases. J Clin Invest 2001;107:7-11.
4. Sioud M, Mellbye O, Forre O. Analysis of the NF-kappa B p65 subunit, Fas antigen, Fas ligand and Bcl-2-related proteins in the synovium of RA and polyarticular JRA. Clin Exp Rheumatol 1998;16:125-34.
5. Han Z, Boyle DL, Manning AM, Firestein GS. AP-1 and NF-κB regulation in rheumatoid arthritis and murine collagen-induced arthritis. Autoimmunity 1998;28:197-208.
6. Seetharaman R, Mora AL, NaboznyG, Boothby M, Chen J. Essential role of T cell NF-kappa B activation in collagen-induced arthritis. J Immunol 1999;163:1577-83.
7. Aupperle K, Bennett B, Han Z, Boyle D, Manning A, Firestein G. NF-kappaB regulation by I kappa B kinase-2 in rheumatoid arthritis synoviocytes. J Immunol 2001;166:2705-11.
8. Miagkov AV, Kovalenko DV, Brown CE, Didsbury JR, Cogswell JP, Stimpson SA, et al. NF-kappaB activation provides the potential link between inflammation and hyperplasia in the arthritic joint. Proc Natl Acad Sci USA 1998;95:13859-64.
9. Tak PP, Gerlag DM, Aupperle KR, van de Geest DA, Overbeek M, Bennett BL, et al. Inhibitor of nuclear factor κB β is a key regulator of synovial inflammation. Arthritis Rheum 2001;44:1897-907.
10. Bhagwar S, Bennett BI, Satoh Y, O'Leary EC, Leisten J, Firestein GS, et al. The small molecule IKK2 inhibitors SPC 839 is efficacious in an animal model of arthritis [abstract]. Arthritis Rheum 2001;44(suppl):S213.
11. Lavon I, Goldberg I, Amit S, Landsman L, Jung S, Tsuberi BZ, et al. High susceptibility to bacterial infection, but no liver dysfunction, in mice compromised for hepatocyte NF-kappaB activation. Nat Med 2000;6:573-7.
12. Li ZW, Chu W, Hu Y, Delhase M, Deerinck T, Ellisman M, et al. The IKKbeta subunit of IkappaB Kinase (IKK) is essential for nuclear factor kappaB activation and prevention of apoptosis. J Exp Med 1999;189:1839-45.
13. Manna SK, Aggarwal BB. Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression. J Immunol 1999;162:2095-102.
14. Yin MJ, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 1998;396:77-80.
15. Shimada T, Kawai T, Takeda K, Matsumoto M, Inoue J, Tatsumi Y, et al. IKK-i, a novel lipopolysaccharide-inducible kinase that is related to IkappaB kinases. Int Immunol 1999;11:1357-62.
16. Aupperle KR, Bennett BL, Mercurio F, Boyle DL, Firestein GS. Expression and regulation of inducible I kappa B kinase (IKK-i) in human fibroblast-like synoviocytes. Cell Immunol 2001;214:54-9.
17. Robinson MJ, Cobb MH. Mitogen-activated protein kinase pathways. Curr Opin Cell Biol 1997;9:180-5.
18. Seger R, Krebs EG. The MAPK signaling cascade. FASEB J 1995;9:726-35.
19. Fanger GR, Gerwins P, Widmann C, Jarpe MB, Johnson GL. MEKKs, GCKs, MLKs, PAKs, TAKs, and tpls: upstream regulators of the c-Jun amino-terminal kinases? Curr Opin Genet Dev 1997;7:67-76.
20. Hibi M, Lin A, Smeal T, Minden A, Karin M. Identification of an oncoprotein- and UV- responsive protein kinase that binds and potentiates the c-Jun activation domain. Genes Dev 1993;7:2149-60.
21. Schett G, Tohidast-Akrad M, Smolen JS, Schmid BJ, Steiner CW, Bitzan P, et al. Activation, differentiatial localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-JUN N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthritis. Arthritis Rheum 2000;43:2501-12.
22. Han Z, Boyle DL, Aupperle KR, Bennett B, Manning AM, Firestein GS. Jun-N-Terminal kinase in rheumatoid arthritis. J Pharmacol Exp Ther 1999;291:124-30.
23. Weston CR, Davis RJ. The JNK signal transduction pathway. Curr Opin Genet Dev 2002;12:14-21.
24. Feng Y, Schreiner GF, Chakravarty S, Liu DY, Joly AH. Inhibition of the mitogen activated protein kinase, p38 alpha, prevents proinflammatory cytokine induction by human adherent mononuclear leukocytes in response to lipid loading. Atherosclerosis 2001;158:331-8.
25. Kotlyarov A, Neininger A, Schubert C, Eckert R, Birchmeier C, Volk HD, et al. MAPKAP kinase 2 is essential for LPS-induced TNF-alpha biosynthesis. Nat Cell Biol 1999;1:94-7.
26. Badger AM, Griswold DE, Kapadia R, Blake S, Swift BA, Hoffman SJ, et al. Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis. Arthritis Rheum 2000;43:175-83.
27. Fijen JW, Zijlstra JG, De Boer P, Spanjersberg R, Cohen Tervaert JW, Van Der Werf TS, et al. Suppression of the clinical and cytokine response to endotoxin by RWJ-67657, a p38 mitogen-activated protein-kinase inhibitor, in healthy human volunteers. Clin Exp Immunol 2001;124:16-20.
28. Cuenda A, Rouse J, Doza YN, Meier R, Cohen P, Gallagher TF, et al. SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett 1995;364:229-33.
29. Han Z, Boyle DL, Chang L, Bennett B, Karin M, Yang L, et al. c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J Clin Invest 2001;108:73-81.
30. Han Z, Chang L, Yamanishi Y, Karin M, Firestein GS. Joint damage and inflammation in c-Jun N-terminal kinase 2 knockout mice with passive murine collagen-induced arthritis. Arthritis Rheum 2002;46:818-23.
31. Fleming Y, Armstrong CG, Morrice N, Paterson A, Goedert M, Cohen P. Synergistic activation of stress-activated protein kinase 1/c-Jun N-terminal kinase (SAPK1/JNK) isoforms by mitogen-activated protein kinase kinase 4 (MKK4) and MKK7. Biochem J 2000;352(Pt 1):145-54.
32. Lawler S, Fleming Y, Goedert M, Cohen P. Synergistic activation of SAPK1/JNK1 by two MAP kinase kinases in vitro. Curr Biol 1998;8:1387-90.
33. Whitmarsh AJ, Cavanagh J, Tournier C, Yasuda J, Davis RJ. A mammalian scaffold complex that selectively mediates MAP kinase activation. Science 1998;281:1671-4.
34. Schaeffer HJ, Catling AD, Eblen ST, Collier LS, Krauss A, Weber MJ. MP1: a MEK binding partner that enhances enzymatic activation of the MAP kinase cascade. Science 1998;281:1668-71.
35. Sundarrajan M, Boyle DL, Chabaud M, Hammaker D, Firestein GS. Expression and regulation of the MAP kinase kinases, MKK4 and MKK7, in rheumatoid arthritis. Arthritis Rheum 2003;48:2450-60.
36. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002;298:1911-12.